PB2059: SENSITIVITY AND SUBGROUP ANALYSES FURTHER SUPPORT CLINICAL SIMILARITY IN EFFICACY BETWEEN ABP 959 AND ECULIZUMAB REFERENCE PRODUCT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

• Austin Kulasekararaj,
• Francesco Lanza,
• Alexandros Arvanitakis,
• Saskia Langemeijer,
• Satheesh Chonat,
• Jia Cao,
• Vincent Chow,
• Haby Henary

Affiliations

Austin Kulasekararaj

1 King’s College Hospital NHS Foundation Trust, National Institute of Health Research/Wellcome King’s Clinical Research Facility and King’s College London, London, United Kingdom

Francesco Lanza

2 Azienda USL della Romagna, Ravenna, Italy

Alexandros Arvanitakis

3 Skånes Universitetssjukhus Malmö, Malmo, Sweden

Saskia Langemeijer

4 Radboud Universitair Medisch Centrum, Nijmegen, Gelderland, Holland, The Netherlands

Satheesh Chonat

5 Emory University and Children’s Healthcare of Atlanta, Department of Pediatrics, Atlanta, United States

Jia Cao

6 Amgen Inc., Thousand Oaks, United States

Vincent Chow

6 Amgen Inc., Thousand Oaks, United States

Haby Henary

6 Amgen Inc., Thousand Oaks, United States